Related Experiment Videos

Mutations affecting conserved cysteine residues within the extracellular domain of Neu promote receptor dimerization

P M Siegel1, W J Muller

  • 1Institute for Molecular Biology and Biotechnology, McMaster University, Hamilton, ON, Canada.

Insights

Overexpression of the Neu/ErbB-2 receptor tyrosine kinase drives breast cancer. Mutations cause receptor dimerization via disulfide bonds, leading to constitutive activation and tumor formation.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Neu/ErbB-2 receptor tyrosine kinase overexpression is linked to human breast cancer.
  • Neu expression in transgenic mice induces mammary tumors.
  • Somatic activating mutations in the neu transgene contribute to tumor development.

Purpose of the Study:

  • To investigate the role of cysteine residues in Neu receptor activation.
  • To determine the mechanism of oncogenic activation of Neu.
  • To explore the role of disulfide bonds in Neu receptor dimerization.

Main Methods:

  • Mutagenesis of conserved cysteine residues in the Neu receptor.
  • Assessment of the transforming potential of mutated Neu receptors.
  • Analysis of receptor dimerization and activation through disulfide bond formation.

Main Results:

  • Mutation of specific cysteine residues led to oncogenic activation of Neu.
  • Altered Neu receptors exhibited constitutive dimerization dependent on disulfide bonds.
  • 2-mercaptoethanol disrupted the transforming activity of mutant Neu receptors.

Conclusions:

  • Oncogenic activation of Neu is driven by constitutive disulfide bond-dependent dimerization.
  • Targeting disulfide bond formation may offer therapeutic strategies for Neu-driven cancers.
  • Understanding Neu receptor dimerization is crucial for breast cancer research.

Related Concept Videos